Is AMRN stock a good buy?
Out of 3 analysts, 0 (0%) are recommending AMRN as a Strong Buy, 0 (0%) are recommending AMRN as a Buy, 2 (66.67%) are recommending AMRN as a Hold, 0 (0%) are recommending AMRN as a Sell, and 1 (33.33%) are recommending AMRN as a Strong Sell.
Will Amarin stock go back up?
Amarin Corporation PLC (NASDAQ:AMRN) The 7 analysts offering 12-month price forecasts for Amarin Corporation PLC have a median target of 3.00, with a high estimate of 9.00 and a low estimate of 1.50. The median estimate represents a +122.22% increase from the last price of 1.35.
Does Amarin pay dividends?
The current TTM dividend payout for Amarin (AMRN) as of June 29, 2022 is $0.00.
Will Amarin be acquired?
US firm Valeant Pharmaceuticals International (formerly known as ICN Pharmaceuticals) has agreed to acquire UK-headquartered Amarin Corp's US unit and most of Amarin Pharmaceuticals Inc's US products for a consideration of $38 million.
Why is Amarin stock so low?
Unfortunately for Amarin, a federal court ruling opened Vascepa up to competition from generic versions in 2020. The stock is sliding today because first-quarter earnings results suggest the company's commercialization strategy isn't working.
Is Amarin a good company?
Is Amarin a good company to work for? Amarin has an overall rating of 3.5 out of 5, based on over 111 reviews left anonymously by employees. 47% of employees would recommend working at Amarin to a friend and 23% have a positive outlook for the business. This rating has decreased by -10% over the last 12 months.
Who owns Amarin Pharmaceuticals?
NovartisThe Medicines Company was acquired by Novartis for $9.7 billion despite having no revenue (versus $600 million for Amarin) and no FDA approval at the time (Amarin has FDA and EU approval). Amarin has a star drug and would be a prime takeover target for Big Pharma.
What pharmaceutical company makes vascepa?
AmarinAmarin is a rapidly growing, innovative pharmaceutical company focused on commercializing and developing therapeutics to cost-effectively improve cardiovascular health. Amarin's lead product, VASCEPA, is a prescription drug.